131 related articles for article (PubMed ID: 12099742)
1. Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs.
Tomioka H; Sato K; Shimizu T; Sano C
J Infect; 2002 Apr; 44(3):160-5. PubMed ID: 12099742
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
Tomioka H; Sano C; Sato K; Shimizu T
Int J Antimicrob Agents; 2002 Feb; 19(2):139-45. PubMed ID: 11850167
[TBL] [Abstract][Full Text] [Related]
3. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Sato K; Tomioka H; Sano C; Shimizu T; Sano K; Ogasawara K; Cai S; Kamei T
J Antimicrob Chemother; 2003 Aug; 52(2):199-203. PubMed ID: 12865388
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
Lu T; Drlica K
J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.
Rastogi N; Labrousse V; Goh KS
Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093
[TBL] [Abstract][Full Text] [Related]
6. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Bhusal Y; Shiohira CM; Yamane N
Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Akaki T; Kajitani H; Kawahara S; Sakatani M
Antimicrob Agents Chemother; 1999 Dec; 43(12):3001-4. PubMed ID: 10582897
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis.
Rey-Jurado E; Tudó G; Martínez JA; González-Martín J
Tuberculosis (Edinb); 2012 May; 92(3):260-3. PubMed ID: 22342247
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
Cai S; Sato K; Shimizu T; Yamabe S; Hiraki M; Sano C; Tomioka H
J Antimicrob Chemother; 2006 Jan; 57(1):85-93. PubMed ID: 16303883
[TBL] [Abstract][Full Text] [Related]
10. New drugs for tuberculosis.
Grassi C; Peona V
Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571
[TBL] [Abstract][Full Text] [Related]
11. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Cynamon M; Sklaney MR; Shoen C
J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.
Ramaswamy S; Musser JM
Tuber Lung Dis; 1998; 79(1):3-29. PubMed ID: 10645439
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
16. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].
Lu Y; Wang B; Zhao WJ; Zheng MQ; Li P; Fu L; Liang BW
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Sep; 33(9):675-8. PubMed ID: 21092635
[TBL] [Abstract][Full Text] [Related]
17. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
18. A whole blood bactericidal assay for tuberculosis.
Wallis RS; Palaci M; Vinhas S; Hise AG; Ribeiro FC; Landen K; Cheon SH; Song HY; Phillips M; Dietze R; Ellner JJ
J Infect Dis; 2001 Apr; 183(8):1300-3. PubMed ID: 11262217
[TBL] [Abstract][Full Text] [Related]
19. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
20. [Molecular mechanisms of drug resistance of Mycobacterium tuberculosis].
Stepanshin IuG; Stepanshina VN; Shemiakin IG
Antibiot Khimioter; 1999; 44(4):39-43. PubMed ID: 10483496
[No Abstract] [Full Text] [Related]
[Next] [New Search]
